Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -431K | 0 | 0 | 0 | 0 |
| Operating Income | -393M | -151M | -101M | -70M | -56M |
| EBITDA | -393M | -151M | -101M | -70M | -55M |
| Net Income | -360M | -110M | -86M | -69M | -55M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$30.38
+0.30% today
1Y Change
+22.20%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viking Therapeutics, Inc. (VKTX) is a Healthcare stock with a market cap of $3.48B and listed on NASDAQ. The stock last traded around $30.38 and up 22.2% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -215.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -215.8%, free cash flow -217.4% with operating margin 0.0% and ROIC -100.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VKTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VKTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VKTX Max Drawdown
-45.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VKTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$55.0M
+20.2% YoY
Free Cash Flow
-$47.6M
+1.7% YoY
Revenue Growth
+0.0%
EPS Growth
-215.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -431K | 0 | 0 | 0 | 0 |
| Operating Income | -393M | -151M | -101M | -70M | -56M |
| EBITDA | -393M | -151M | -101M | -70M | -55M |
| Net Income | -360M | -110M | -86M | -69M | -55M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 166M | 27M | 56M | 37M | 26M |
| Total Assets | 716M | 908M | 368M | 169M | 211M |
| Total Liabilities | 77M | 28M | 20M | 23M | 9M |
| Shareholder Equity | 639M | 880M | 348M | 145M | 202M |
| Total Debt | 137K | 1M | 1M | 2M | 29K |
| Net Debt | -166M | -26M | -54M | -35M | -26M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
48M
+1.7% YoY
Capital Expenditures
0
Free Cash Flow
48M
+1.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-71.3%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.